EVIIVE develops a minimally invasive diagnostic and disease‑monitoring approach for sepsis using liquid biopsies derived from extracellular vesicle (EV) analyses. The final product is intended to be assay kits that customers can use to process liquid biopsies and analyze results with existing flow cytometers. The company also plans to offer novel EV biomarker discovery services for diseases with high unmet needs in detection and monitoring. CEO Dr. Kevin Ho Wai Yim (UZH) co‑founded EVIIVE with CSO Dr. Richard Chahwan. The article cites epidemiology that in the EU/US around 20% of newborns (≈1,600,000 per year) show sepsis symptoms and that over 75,000 children are diagnosed with severe sepsis each year in the US with a similar number in the EU (≈150,000 per year). At a target charge of USD 100 per test and three tests per patient, the article estimates revenue of approximately USD 525 million per year. Venture Kick funding will be used to pay a research assistant and cover validation reagent and equipment costs.

Total raised

$45M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2024